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Introduction: Certain types of the Human Papillomavirus (HPV) are sexually transmitted and highly associated with
development of cervical dysplasia and cervical cancer but the distribution of HPV infection in the North, particularly
amongst First Nations, Metis, and Inuit peoples, is little known. The purposes of the study are to identify the
prevalence of type-specific HPV infections and the association of different HPV types with cervical dysplasia among
women in Northern Canada.
Methods: This was a cross-sectional study with attendants of the routine or scheduled Pap testing program in the
Northwest Territories (NWT), Nunavut, Labrador and Yukon, Canada. Approximately half of each sample was used
for Pap test and the remaining was used for HPV genotyping using a Luminex-based method. Pap test results, HPV
types, and demographic information were linked for analyses.
Results: Results from 14,598 specimens showed that HPV infection was approximately 50% higher among the
Aboriginal than the non-Aboriginal population (27.6% vs. 18.5%). Although the most common HPV type detected
was HPV 16 across region, the prevalence of other high risk HPV types was different. The age-specific HPV
prevalence among Aboriginal showed a ‘U’ shape which contrasted to non-Aboriginal. The association of HPV
infection with cervical dysplasia was similar in both Aboriginal and non-Aboriginal populations.
Conclusions: The HPV prevalence was higher in Northern Canada than in other Areas in Canada. The prevalence
showed a higher rate of other high risk HPV infections but no difference of HPV 16/18 infections among Aboriginal
in comparison with non-Aboriginal women. This study provides baseline information on HPV prevalence that may
assist in surveillance and evaluation systems to track and assess HPV vaccine programs.
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Cervical cancer is the second most common cancer of the
women worldwide. In Canada invasive cervical cancer and
associated mortality among Aboriginal women have been
2–4 times higher than among non-Aboriginal women
[1-4]. From the Statistics Canada 2006 census Aboriginal
groups make up more than 50% of the population in the
Northwest Territories (NWT) [5] (First Nations, Metis,
and Inuit), 85% of the population in Nunavut [6] (predo-
minantly Inuit), 35% in Labrador [7] (Metis, Inuit, and* Correspondence: Howard.Morrison@phac-aspc.gc.ca
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provided the original work is properly cited.First Nations) , and 25% in the Yukon [8] (predominantly
First Nations). Increased risk of cervical cancer in Aborigi-
nal women has been consistently observed in various re-
gions across Northern Canada [2,9,10]. The gap in cervical
cancer and associated mortality between the Aboriginal
and non-Aboriginal groups has important implications for
cancer control policy. Implementation and evaluation of
cervical cancer prevention programs in Aboriginal women
may require a different approach.
Human Papillomavirus (HPV) is a common sexually
transmitted infection worldwide. Persistent infection with
specific types of the virus is necessary for the development
of invasive cervical cancer and its precursor lesions [11].
HPV is detected in almost 100% of women with invasiveicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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approximately 70% of all cases [12,13]. In Canada HPV
16/18 prevalence has been reported in 56.2% of high grade
precursor lesions [14]. HPV 16/18 prevalence can vary by
geography and ethnicity. Therefore, determination of
type-specific HPV prevalence in a region may be one of
the important steps towards cervical cancer prevention.
Only very limited regional data [2,3,15] provide HPV
prevalence in Northern Canada which appears different
with that of the general population. Population based
research on HPV and related outcomes in the North
could fill this information gap. For cervical cancer pre-
vention and early detection of pre-cancerous lesions,
routine Papanicolaou smear (Pap) test screening is of-
fered in all regions of Northern Canada with good cove-
rage of targeted population. In 2008, 88%, 74%, 83%, and
81% of women aged 18–69 in NWT, Nunavut, Labrador,
and Yukon respectively, were reported as having had a
Pap test in the previous three years [16]. It was therefore
considered a practical and efficient approach to examine
HPV prevalence as part of routine Pap smear screening.
The purpose of this study is to measure the prevalence of
HPV infections by type and region and to determine their
impacts on cervical dysplasia across Northern Canada.
Methods
Study population
This was a cross-sectional study including all women aged
14 years or older who presented for a regular Pap test in
the four regions of Northern Canada: NWT (April, 2008 -
March, 2009), Nunavut (January, 2008 - March, 2009),
Labrador (February - November, 2010), and Yukon
(March, 2009 - June, 2010). Women with a cervical cancer
history and those who chose to opt-out were excluded
from the study. Only the first sample collected was kept
for analysis for women with more than one Pap smear
performed over the study period. An opt-in consent
process was used in Yukon which was different with the
other jurisdictions. Given the universal coverage of the
health care system in Canada there are no other Pap test
providers in these areas.
Authority and licensing
This research received ethical approval from the Health
Canada Ethics Review Board, McGill University Ethics
Review, and the local health authorities including NWT
Department of Health and Social Services, Stanton
Territorial Health Authority, the Yukon Department of
Health and Social Services, and the Yukon Scientists
and Explorers Act License. A Northern research licence
was also obtained from Aurora Research Institute in the
NWT. The project was facilitated by four data collection
sites and the manuscript was reviewed by community
stakeholders before being submitted for publication.Data source
Pap test screening is performed in each Territory and the
Labrador health region in Canada. It is offered to all
women aged 18–69 and young women aged 14–18 who
wish to participate. Pap smears are collected at commu-
nity health centres, medical clinics, or hospitals whichever
appropriate. Pap test registration form is used to assemble
personal record and demographic information on site.
Demographic details including Aboriginal status, age, and
region information were abstracted from the routine Pap
test registration form. Aboriginal status was only available
among NWT, Nunavut, and Yukon datasets. Only area
code (residence in Aboriginal area or non-Aboriginal area)
was available in the Labrador dataset. Data were collected,
organised, and owned by the local health authorities.
Specimen collection and preparation
Samples from NWT and Nunavut were collected in liquid
based cytology (LBC) medium (SurePathW) and were
shipped to the DynaLife Medical Laboratory in Edmonton,
where cytology was read and remaining half of the speci-
men was kept for HPV testing. Samples from Labrador
were also collected in SurePath LBC medium and shipped
to Newfoundland Public Health Laboratory for Pap test
interpretation. In Yukon, conventional Pap smear slides
were taken and shipped to the Cervical Cancer Screening
Laboratory, BC Cancer Control Agency. A sample for
HPV testing was prepared by taking a second cervical
sample and by rinsing the brushes in LBC medium.
Samples for HPV genotyping were shipped from all four
areas to the National Microbiology Laboratory (NML) in
Winnipeg, Canada. Cervical cytology and HPV testing
were done independently to eliminate the potential for re-
porter bias.
HPV typing
For HPV genotyping an “in house” Luminex assay [17]
developed at the NML was used. This assay detects 45
high risk and low risk HPV types. Comparison against
the Linear Array (Roche) [17] and other HPV genotyping
kits [18] showed that this Luminex assay is comparable
to other commercial genotyping methods. The 45 HPV
types included 23 of the 25 IARC high risk (HR) types
found in group 1, 2a, and 2b (HPV 16, 18, 26, 30, 31, 33,
35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73, 82
and 85) [19], and other 22 types considered of low (LR)
or unknown risk (6, 11, 13, 32, 40, 42, 43, 44, 54, 61, 62,
71, 72, 74, 81, 83, 84, 86, 87, 89, 90, and 91) [19].
Pap smear testing
Cytological reports were issued according to the Bethesda
system [20,21]. The results were classified as: normal
(including benign), atypical squamous cells of undetermined
significance (ASC-US), low-grade squamous intraepithelial
Table 1 HPV type distribution by cytological results in Northern Canada1
HPV2 typing Cytological results3 Total
Normal ASC-US LSIL HSIL+ASC-H n %
HPV negative 10488 92 46 19 10645 74.1%
HPV positive 2891 320 372 145 3728 25.9%
Total 13379 412 418 164 14373 100.0%
HR-HPV
163 485 79 85 71 720 5.0%
31 236 44 31 17 328 2.3%
66 172 30 50 2 254 1.8%
45 171 27 23 10 231 1.6%
59 179 20 26 6 231 1.6%
18 141 32 41 10 224 1.6%
51 151 17 47 4 219 1.5%
39 153 18 40 8 219 1.5%
58 148 21 27 15 211 1.5%
67 142 16 18 6 182 1.3%
52 132 21 13 12 178 1.2%
70 131 12 21 2 166 1.2%
56 99 8 36 5 148 1.0%
33 94 15 24 9 142 1.0%
35 85 9 16 11 121 0.8%
73 59 6 10 1 76 0.5%
53 48 7 18 1 74 0.5%
68 35 3 4 1 43 0.3%
30 20 7 5 0 32 0.2%
69 24 2 4 0 30 0.2%
85 24 3 3 0 30 0.2%
82 11 2 5 0 18 0.1%
26 3 2 3 1 9 0.1%
Total 2743 401 550 192 3886 27.0%
LR-HPV
42 159 10 14 2 185 1.3%
62 158 9 7 0 174 1.2%
81 129 12 11 2 154 1.1%
6 112 16 22 1 151 1.1%
89 107 9 9 0 125 0.9%
72 101 2 3 1 107 0.7%
54 94 3 9 0 106 0.7%
83 75 4 6 0 85 0.6%
84 70 7 3 0 80 0.6%
40 55 6 6 2 69 0.5%
74 62 6 1 0 69 0.5%
90 53 2 12 0 67 0.5%
86 43 3 1 0 47 0.3%
11 27 9 8 0 44 0.3%
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Table 1 HPV type distribution by cytological results in Northern Canada1 (Continued)
44 48 1 0 0 49 0.3%
43 15 2 5 1 23 0.2%
32 19 1 0 1 21 0.1%
87 18 0 1 0 19 0.1%
13 10 3 2 0 15 0.1%
61 9 1 0 0 10 0.1%
91 2 1 5 0 8 0.1%
71 1 0 0 0 1 0.0%
Total 1367 107 125 10 1609 11.2%
Note:
13 Records with suspicious or malignant carcinoma are not involved in the table.
2In our study HPV type 2, 3, 7, 10, 27, 28, 29, 34, 57, 78, and 94 could not be detected so there were no results for Species 2, 4 and 12. Moreover, HPV type 7 from
species A8 and HPV 34 from species A11 were removed because the Luminex assay could not detect them.
3Records with pap test results unsatisfactory are not included in the table.
Jiang et al. Infectious Agents and Cancer 2013, 8:25 Page 4 of 11
http://www.infectagentscancer.com/content/8/1/25lesion (LSIL), and high-grade squamous intraepithelial lesion
(HSIL). Samples with atypical squamous cells (ASC-H),
where HSIL could not be excluded, were added to the
HSIL category. To be consistent with reported data world-
wide we classified LSIL and HSIL as abnormal categories
for the correlation analysis and impact assessment. ASC-
US cases were not included in this part of analysis.
Statistical analyses
Data preparation
Demographic information, HPV types and Pap test results
were linked for HPV prevalence analysis. In the linkage
dataset, 764 records (approximately 5% of collected data
in the study) with one or more items of missing value
were excluded from the analysis; 485 missing in age or
age-group, 327 in ethnic status or ethnic area, and 399 in
Pap test including 126 unsatisfactory cytology results.
HPV_s and HR_s were defined as cases with only a
single type of HPV infection and cases with only a single
type of high risk HPV infection, respectively. Similarly,
HPV_m and HR_m were defined as samples with two or
more types of HPV or HR HPV infection. Samples with
two or more HPV types were counted in for each type
in type-specific analysis.
Analysis
Prevalence rates for type-specific HPV infection and
cervical dysplasia were computed. Based on the 2008
census data among women in the NWT region [5] as
the standard, the age-adjusted prevalence rates (AAPR)
were calculated for area comparison. The overall preva-
lence rate in Northern Canada was also weighted by
population size [5-8] by region.
A multivariate logistic regression analysis was used to
explore the associations between HPV infection and
cervical dysplasia, adjusted for Aboriginal status, age,and region. Odd Ratios (ORs) were calculated by differ-
ent level: (a) infection with any HPV type, single HR in-
fection, multiple HR infection, single LR infection,
multiple LR infection, and infection with both LR and
HR types, relative to no HPV infection, and (b) infection
with both HR and LR HPV types relative to a single LR
HPV infection.
The proportion of cervical dysplasia caused by HPV
infection in Northern Canada was measured by the ex-
posure attributable risk fraction (ARF) and the popula-
tion attributable risk fraction (PAR). In calculating the
PAR, to avoid duplicate counting of those infected with
both HR and LR, the exposed population was first strati-
fied into those infected with only HR, only LR, and both.
The PARs were summed across the strata. ORs are used
in the calculation of both ARF and PAR: ARF = (OR-1)/
OR and PAR = (Number of exposed cases x ARF)/total
cases in the population. Furthermore, PAR of HR HPV in-
fection = (No. of HR_s cases x ARF reference to HPV
negative + No. of only multiple HR cases x ARF reference
to HPV negative + No. of both HR and LR infected cases
x ARF reference to LR HPV) / total cases [22].
All data management and analyses were carried out using
Statistical Analysis System 9.1. Two-tailed p value < 0.05
was the criteria to determine the statistical significant [23].Results
A total of 14598 cytology samples were collected and
tested from NWT (n = 6940), Nunavut (n = 4683), Labra-
dor (n = 1370), and the Yukon (n = 1605). In NWT and
Nunavut the study covered more than 95% of the Program
targeted population, respectively; but only 77% and 27% in
Labrador and the Yukon in the study period. In this
study, approximately 42% of women were non-
Aboriginal and 58% were Aboriginal. The overall mean
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HPV-DNA was detected in 26% of subjects (Table 1).
After weighting the four regional population sizes from
census data, the overall prevalence rate in Northern
Canada was estimated to be 25.2%. Although the specific
prevalence of HPV types was dissimilar among regions,
the highest prevalence HPV types detected were HPV-16
(5.0%), HPV-31 (2.3%), HPV-66 (1.8%), HPV-45 (1.6%),
HPV-59 (1.6%), and HPV-18 (1.6%). HPV typeFigure 1 HPV infection type distribution in NWT, Nunavut, Labrador adistributions are different by region (Figure 1). Among
HPV infected samples, 79% had an HR type, 33% had
multi-types, and 25% had HPV 16/18. The overall preva-
lence of HPV_m, HR_s, HR_m, and LR_s were 8.4%, 13%,
4.0%, and 4.7%, respectively.
Age specific
The age specific HPV prevalence rate ranged between
13% and 48% (Figure 2). The highest prevalence of HR
HPV infection and HPV 16/18 was among women aged
less than 20 years, with decreasing prevalence until age
group 40–49. HPV prevalence was higher in the Abori-
ginal than the non-Aboriginal women in each age group;nd Yukon, Canada.
Figure 2 Proportion of HPV types by agegroup, in NWT, Nunavut, Labrador and Yukon, Canada.
Jiang et al. Infectious Agents and Cancer 2013, 8:25 Page 6 of 11
http://www.infectagentscancer.com/content/8/1/25in particular among women aged 50 or over (Figure 3).
It is of note on the trend that the prevalence of HPV in-
creased again after age 50 thus forming a U-shaped
curve in the Aboriginal women, but following a mono-
tonic decrease with age in the non-Aboriginal women.
Regional and ethnic differences in HPV prevalence
In Table 2, HPV prevalence rate in NWT, Nunavut,
Labrador, and Yukon was 23.2%, 31.5%, 21.4%, and 24.5%;
respectively. After adjusting by the NWT 2008 census data
for women as a standard population AAPRs changed to
22.7%, 28.0%, 21.1%, and 23.5%; respectively. Any type
HPV and HR type HPV AAPRs were significantly higher
among the Aboriginal than the non-Aboriginal women.
However the HPV 16/18 AAPRs were not statistically dif-
ferent by ethnic group across region. In addition the HR
HPV prevalence rates accounted for a higher percentage
in any HPV infection among the Aboriginal than among
the non-Aboriginal population. HPV 16/18 comprised
about 30% of all HR-HPV infection in all four regions.Figure 3 HPV prevelance by agegroup among Aboriginal and Non-AbPrevalence by Pap test results
Overall, 4.0% of Pap test results were abnormal (HSIL
and LSIL); 4.7% in Aboriginal and 3.1% in non-
Aboriginal group (Table 3). Among the women with
normal cytology (92.3%), the HPV prevalence rate in the
Aboriginal was 26% in comparison to 15% of the non-
Aboriginal group. However, among women with abnormal
Pap test, the HPV prevalence was 91.6% in the Aboriginal
versus 82.9% in the non-Aboriginal group. Stratified ana-
lyses on HPV infection by cytological results in women
aged < 30 and aged 30 or over among the Aboriginal and
the non-Aboriginal showed that distributions of HPV
prevalence by cytological result were similar in different
ethnic and age groups. In particular, the relative prevalence
of HPV 16/18 among HSIL was not significantly different
in Aboriginal (46.9) vs Non-Aboriginal women (50.0), as
shown in Table 3. Among women with normal cytology
419 (5.4%) and 182 (3.4%) were infected with HPV 16/18 in
the Aboriginal and non-Aboriginal group, respectively. The
corresponding numbers for HR HPV other than 16/18original women in NWT, Nunavut, Labrador and Yukon, Canada.
Table 2 HPV infection prevalence rate among women in Northern Canada, 2008-2010
Region # Any type HR_HPV HPV 16/18
# % AAPR* # % AAPR # % AAPR
(95% CI) (95% CI) (95% CI)
NWT 6724 1561 23.2 22.7 (21.5, 24.0) 1205 17.9 17.5 (16.5, 18.6) 352 5.2 4.9 (4.4, 5.5)
Nunavut 4654 1468 31.5 28.0 (26.3, 29.6) 1205 25.9 22.2 (20.8, 23.7) 387 8.3 4.5 (2.8, 6.3)
Labrador** 1370 293 21.4 21.1 (18.6, 23.6) 218 15.9 15.8 (13.6, 18.0) 73 5.3 5.5 (4.2, 6.8)
Yukon 1542 378 24.5 23.5 (20.9, 26.1) 284 18.4 17.7 (15.4, 19.9) 96 6.2 6.0 (4.7, 7.3)
Aboriginal 8446 2623 31.1 27.6 (25.5, 29.8) 2104 24.9 21.6 (19.7, 23.5) 630 7.5 6.1 (5.1, 7.0)
Non-Aboriginal 5844 1077 18.4 18.5 (16.2, 20.8) 808 13.8 13.8 (11.8, 15.7) 278 4.8 4.9 (3.9, 6.0)
P*** <0.01 <0.01 >0.05
*AAPRs (Age-Adjusted Prevalence Rates) were calculated using NWT 2008 standard population.
**Labrador data only had area code (residence in Aboriginal area or not) instead of Aboriginal Status information.
***P-value is tested for significant difference between Aboriginal and Non-Aboriginal women in each site using Chi-square test.
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bers for all HPV infection were 2004 (26%) and 829 (15%),
respectively.Impact of HPV on cervical abnormalities
After adjusting for Aboriginal status, age, and region, the
logistic regression models showed that the ORs for cer-
vical abnormalities associated with any type HPV, LR_s,
HR_s, only multiple LR infections, only multiple HR infec-
tions and mixed HR and LR infections were 28.9, 5.3, 29.4,
6.2, 71.9, and 35.4, respectively, and that HPV infection
accounted for 85.7% of the cervical abnormalities with
80.6% attributable to high risk HPV infection and 32.5%
attributable to HPV 16/18 infection (Table 4).Table 3 Cytological results by HPV types in Northern Canada
Cytology* Overall Any type HR_HPV
N %** N %*** N %***
Aboriginal 8428 100 2617 31.1 2098 24.9
Normal 7693 91.3 2004 26.0 1526 19.8
ASC-US 294 3.5 241 82.0 219 74.5
LSIL 279 3.3 256 91.8 239 85.7
HSIL 113 1.3 103 91.2 103 91.2
unsatisfactory 49 0.6 13 26.5 11 22.4
Non-Aboriginal 5765 100 1060 18.4 795 13.8
Normal 5404 93.7 829 15.3 583 10.8
ASC-US 110 1.9 72 65.5 64 58.2
LSIL 133 2.3 110 82.7 103 77.4
HSIL 48 0.8 40 83.3 39 81.3
unsatisfactory 70 1.2 9 12.9 6 8.6
Note:
*3 records with suspicious or malignant carcinoma are not involved in the table.
**Overall shown column percentage.
***Type specifics shown row Percentage.Discussions
This study recruited most of the women aged 18–69 (and
most of the incidental consultations for the 14–17 age
group) who attended routine or scheduled pap screening
over an approximately one year time period.
The prevalence of overall HPV infection was 25.2%
which was higher than in most countries [24-27] but
similar to Denmark [28] and the US [29]. HPV preva-
lence rates in both the Aboriginal (31.6%) and non-
Aboriginal women (18.9%) in this study were slightly
higher than those in other studies in Aboriginal [2,15]
and non-Aboriginal [30,31] populations in Canada. The
proportion of HR types among the HPV-positive women
was lower than in British Columbia and Ontario studies
but higher than in a Quebec study [2,30,31].LR_HPV HPV_m HR_m HPV 16/18
N %*** N %*** N %*** N %***
219 2.6 885 10.5 418 5.0 626 7.4
478 6.2 617 8.0 261 3.4 419 5.4
22 7.5 92 31.3 48 16.3 77 26.2
17 6.1 142 50.9 83 29.7 73 26.2
0 0.0 28 24.8 24 21.2 53 46.9
2 4.1 6 12.2 2 4.1 4 8.2
265 4.6 313 5.4 148 2.6 272 4.7
246 4.6 219 4.1 89 1.6 182 3.4
8 7.3 30 27.3 19 17.3 26 23.6
7 5.3 46 34.6 27 20.3 38 28.6
1 2.1 16 33.3 13 27.1 24 50.0
3 4.3 2 2.9 0 0.0 2 2.9
Table 4 Logistic regression analysis of the association between HPV infection and cervical abnormality in NWT,
Nunavut, Labrador and Yukon, Canada
HPV
Infection




Ref. HPV Negative 10488 65
Any Type HPV 2891 517 28.89 (22.24, 37.53) 96.5 85.7
Single-HR 1413 260 29.45 (22.30, 38.90) 96.6 43.2
Single-LR 630 21 5.30 (3.22, 8.74) 81.1 2.9
Multiple-HR 354 151 71.93 (52.55, 98.47) 98.6 25.6
Multiple-LR 114 4 6.16 (2.19, 17.31) 83.8 0.6
HR/LR mix 380 81 35.35 (25.01, 49.98) 97.2 13.5
Total 13379 582
HPV16 or 18 614 193 50.82 (37.85, 68.23) 98.0 32.5
Ref. Single-LR 630 21
HR/LR mix 380 81 6.47 (3.93, 10.66) 84.5 11.8
PAR for HR HPV infection: 80.6
Multiple-HR is HR multiple only.
Adjusted model is adjusted using Age-group, Region, and Aboriginal status. (Labrador is using Aboriginal Area as Aboriginal variables).
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most common HPV types detected in Northern Canada
were HPV-16 and 31 [28,32-36]. The HPV 16/18 prevalence
in the study was relatively lower than all similar studies in
Canada [2,30,31,35], but comparable to studies in Europe
and the US [25,26,28,29,37]. In this study HPV 16/18 com-
prised about 31% of all HR-HPV infections. Several HR
HPV types other than HPV 16/18, such as HPV 31, 39, 45,
51, 59 and 66 were relatively common in Northern Canada.
The prevalence analysis shows that HPV prevalence was
highest among women aged less than 20 years, which is
consistent with other studies [27,30,31,38,39]. This finding
confirms what is already known on the natural history of
HPV infection, which is characterized by higher infection
rates after sexual initiation. In agreement with published
data [2,40], the age adjusted HPV prevalence rate in the
Aboriginal group was higher than that in the non-
Aboriginal group. Inconsistent trends in HPV prevalence
by age were noted in older women, with a decrease or
plateau of HPV prevalence among the non-Aboriginal
group, whereas the Aboriginal group showed an increase
of HPV prevalence (U-shaped age-specific HPV preva-
lence distribution). This has been observed in the other
studies in Canada [2,15,30,31] and from Costa Rica and
other Latin American countries [41,42], with the lowest
prevalence among the age group 40–49. However, from
most of the European literature, with the exception of the
former Soviet Union [33], a decrease in HPV prevalence
after age 20 and a levelling off after age 45, has been
reported [25,26,28,42]. Further study needs to appreciate
what role that social, cultural and lifestyle factors, as well asenvironmental determinants such as access to care may play
in explaining this difference in age distribution.
Noteworthy is that, despite the difference in prevalence of
HPV types and cytological abnormalities between Aboriginal
and Non-Aboriginal women, the proportion of HPV 16/18
in high grade lesion is about 50% in both groups. This is very
similar to the average proportion of HPV 16/18 in HSIL in
North America and worldwide [13]. Since HSILs are the
precursors of invasive cancer, these results suggest that
the current HPV vaccines should be equally applicable to
Aboriginal and Non-Aboriginal women.
Currently routine Pap testing is one of the pillars to pre-
vent cervical cancer. Other studies have found similar Pap
test abnormality rates [2,30]. HPV prevalence was higher in
those women aged < 30 than in older women across the
spectrum of abnormal Pap results. This is consistent with re-
ports showing that HPV infection is common in young
women and most often transient [43-46]. It is expected that
women aged 30 years and older experience more persistent
HR infections than younger women and that HPV-DNA tes-
ting would be able to triage this group for further follow-up.
Among participants with a normal pap test result, 26% of
any type HPV infection among the Aboriginal group and
15% among the non-Aboriginal women (Table 3) translated
into a 28 times higher risk of cervical abnormality than those
with HPV negative (Table 4). By the same token, among 5.4%
of the Aboriginal women and 3.4% of the non-Aboriginal
women with both normal Pap test results and HPV 16/18 in-
fection, they have a 50 times higher risk of cervical abnormal-
ity than those who are HPV negative. Interestingly, similar to
our previous NWT report [47], results seem to indicate an
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mation may be useful in considering HPV testing in cervical
cancer screening programs in Northern Canada.
There are potential limitations in the study. Firstly, no
PCR protocol is ideal for all types of HPV detection. Any of
the above comparisons in prevalence rates must be taken
with caution as we have used the most recent IARC classifi-
cation for HR HPV and a novel (Luminex) detection
method as sensitive as Linear Array but able to detect more
types than other previously reported technologies such as
GP5+/6+, Elisa, or Hybrid Capture [17,18]. Secondly, this
study represents HPV infection at various time points in
the different regions, and does not represent the proportion
of women at risk for disease or cancer related to HPV in-
fection. Of note, there was no full regional coverage of the
targeted populations during the study period. Different re-
gions had different recruitment methods and therefore
rates. Due to an “opt-in” process, the coverage for the
Yukon sites lower than the other regions, and one thus
should be cautious in interpreting the prevalence rates of
the study population for Yukon. In addition, the Aboriginal
status was not available in Labrador. To estimate HPV
prevalence by ethnic group in the entire North in Canada,
we used residence for Aboriginal or non-Aboriginal area in-
stead as the purpose of the study was to understand the se-
verity of HPV prevalence in Northern Canada and each
northern region. Although we provided both crude rates
and age adjusted rates for HPV infection, it still needs to be
cautious to make comparison by region due to substantially
different data collection processes. Finally, it’s worth noting
that routine screening is not recommended by standard
guidelines for young women aged 14–18. In addition Pap
screening is not mandatory for anyone; e.g., NWT has their
own guidelines [48] and Yukon follows a guideline from
British Columbia. Therefore, there may be a selection bias
toward the young age group in data analysis. Nevertheless,
the overall analysis was conducted with and without the
14–18 years age group and the results remained similar.
We suspect also that there may be a potential bias affecting
participation by Aboriginal versus non-Aboriginal people.
Conclusions
In Northern Canada, the prevalence of HPV infection
was higher than other Canadian areas and varied by re-
gion. Between the Aboriginal and the non-Aboriginal
group, the age specific distribution rates of HPV infec-
tions appear to be different; however, the effect of HPV
infection to cervical dysplasia was similar. The relatively
high prevalence of HR-HPV other than HPV 16/18, in
particular among the Aboriginal group, call for further
study to understand the impact of specific predictors
[49]. This study provides baseline information on HPV
prevalence that may assist in surveillance and evaluation
systems to track and assess HPV vaccine programs.Abbreviations
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